ArticleJournal of the Society for Cardiovascular Angiography & Interventions
Intracoronary Brachytherapy for Drug-Eluting Stent Restenosis: Outcomes and Clinical Correlates.
Article in Journal of the Society for Cardiovascular Angiography & Interventions. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Sex-Based Differences in Long-Term Outcomes Following Intravascular Brachytherapy for In-Stent Restenosis.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Intravascular Brachytherapy for In-Stent Restenosis in Patients With Chronic Kidney Disease.Journal of the Society for Cardiovascular Angiography & Interventions · 2025Article
- Lesion Preparation Before Coronary Intravascular Brachytherapy: A Comparison of Plain Balloon Versus Cutting/Scoring Balloon Angioplasty.Journal of the Society for Cardiovascular Angiography & Interventions · 2025Article
- A self-sacrificing anti-inflammatory coating promotes simultaneous cardiovascular repair and reendothelialization of implanted devices.Bioactive materials · 2025Article
- Long-term clinical outcomes of intravascular brachytherapy for multilayer drug-eluting in-stent restenosis.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Article
- The NITRATE-OCT study-inorganic nitrate reduces in-stent restenosis in patients with stable coronary artery disease: a double-blind, randomised controlled trial.EClinicalMedicine · 2024Article
- Peripheral Drug-Coated Balloon for Coronary Drug-Eluting Stent In-Stent Restenosis: Off-Label, Off-Target.Journal of the Society for Cardiovascular Angiography & Interventions · 2024Article
- Resistant Drug-Eluting Stent Restenosis and Resurrection of Intracoronary Brachytherapy: The Lazarus of Contemporary Coronary Intervention.Journal of the Society for Cardiovascular Angiography & InterventionsArticle
- SCAI Expert Consensus Statement on Management of In-Stent Restenosis and Stent Thrombosis.Journal of the Society for Cardiovascular Angiography & InterventionsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to report outcomes of intracoronary brachytherapy (ICBT) in treating drug-eluting stent (DES) in-stent restenosis (ISR) and identify correlated factors. Methods: Patients who underwent ICBT for DES ISR from 2010 to 2021 were included in this single-institution retrospective PCI registry. Patients were treated with balloon angioplasty, laser atherectomy, and/or rotational atherectomy, followed by ICBT at a dose of 18.4-25 Gy delivered at the site of ISR with dose determined by the reference vessel size. The primary outcome was 3-year target lesion failure rate (TLF). Secondary end points were 1-year TLF, target lesion revascularization (TLR), all-cause mortality, and cardiac mortality. Results: In total, 330 consecutive patients presented with 345 treated lesions; 70% were male, age was 66 ± 11 years, 55% were diabetic patients, 62% underwent previous bypass surgery, and 89% were placed with at least 2 stent layers at the treated site. The rate of TLF was 18% at 1 year and 46% at 3 years. All-cause mortality and cardiac mortality rates were 19.8% and 12.3% at 3 years. The number of stent layers was associated with 3-year TLF (1 layer, 33.3%; 2 layers, 47.0%, >3 layers, 60.2%; Conclusion: ICBT for recurrent DES ISR provided low recurrence rates at 1 year, which increased substantially by 3 years. Outcomes were most closely correlated with the number of stent layers, but early restenosis and lower ICBT dose adversely affected early TLF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.